Expert RA upgraded PROMOMED DM's credit rating to ruA
05.03.2026
Corporate
For investors
Industry development
05.03.2026
March 4, 2026, Moscow – PJSC PROMOMED (MOEX: PRMD) (formerly "PROMOMED", the "Company", and together with its subsidiaries– the "Group") announces the successful placement of exchange-traded bonds of the 002P-03 series.
The volume of bond issuance was increased from 4.0 billion rubles to 6.8 billion rubles amid high demand from investors. At the same time, the coupon rate was reduced by 0.5 percentage points during the collection of applications and set at the Bank of Russia's key rate of + 2.2 percentage points. The total investor demand reached 9.4 billion rubles and more than doubled the initial target in terms of placement volume. The funds raised will be used for corporate-wide purposes, including continuing to implement the Group's growth strategy with a focus on the development, production and commercialization of innovative medicines and partially refinancing current obligations. The placement was organized by Alfa-Bank, VTB Capital Trading, Gazprombank, Sber CIB and Sovcombank. Gazprombank acted as the placement agent. The placement took place on the Moscow Stock Exchange. PROMOMED's high credit quality is confirmed by ratings from leading Russian rating agencies. On February 16, 2025, the National Rating Agency (NRA) assigned the company a credit rating of A|ru| with a stable outlook. In June 2025, the Expert RA rating agency confirmed the company's credit rating at ruA, with a stable outlook. The Company adheres to a conservative approach to debt management and focuses on maintaining the ratio of net debt to adjusted EBITDA at a level not higher than 2.5x.
Timofey Solovyov, Director of Finance at PROMOMED PJSC, noted: "We are systematically implementing the strategy of balanced management of the Company's portfolio of obligations, optimizing the cost of funding and repayment schedule, providing financial flexibility in the implementation of our strategic goals and objectives. The significant oversubscription of the issue reflects the confidence of the investment community in the quality of our business, transparency of financial policy and the Company's ability to consistently develop an innovative portfolio of drugs, strengthening its position in the Russian pharmaceutical market."
The company's structure includes its own unique world-class R&D center and a high—tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company is developing a diversified portfolio of more than 360 medicines in the top 10 segments of the pharmaceutical market. The company's portfolio includes blockbuster drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the company produces drugs for the treatment of diseases in various therapeutic areas: endocrinology, oncology, neurology, autoimmune diseases, infection control, acute and chronic pain, and others. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the company is an active participant in the system of ensuring national drug safety and import independence of the country.
Contacts|
For investors |
For the media |
Statement of Limitation of liability
This message and the information contained therein are not:
- an offer to purchase any securities,
- an invitation to make offers to purchase any securities,
- as part of such offers or invitations,
- advertising of securities in the Russian Federation or other jurisdictions,
- an offer to purchase medicines,
- advertising of medicines,
- by encouraging or recommending transactions,
- and is also not subject to interpretation as such.
Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.
Neither this announcement nor any part of it should serve as a basis for making any investment decisions and/or decisions on the use of any medicines.
The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the only source of information when making an investment decision.
Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page. https://e-disclosure.ru/portal/company.aspx?id=38533
The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions provided in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). An indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.
The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.
The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office
